NCT02403505Active, not recruitingPhase 1
Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating CEA Positive Rectal Cancer
Conducting an Early Phase Clinical Trial to Assess for CEA Antigen Presentation Therapeutic Biological Product Mix Activity That Suggests the Potential for Clinical Benefits of CEA Positive Rectal Cancer Patients.
Source: ClinicalTrials.gov · Last updated 28 May 2026
Brief summary (registry, in English)
Conducting an early phase clinical trial to assess CEA Antigen Presentation Therapeutic Biological Product Mix activity that suggests the potential for clinical benefit of CEA positive rectal cancer patients. 1. Treat CEA positive rectal cancer via Trained Immunity. 2. Activate human CEA Protein Antigen Presentation Reaction. 3. The human antigen presenting cells (APCs) can treat the CEA protein antigen into small peptide fragments, and then kill CEA positive rectal cancer cells in vivo.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 15 Mar 2015
- Start date
- 28 Dec 2021
- Primary completion date
- 28 Nov 2026
- Lead sponsor
- Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
- Diseases
- Colorectal cancer
- NCT number
- NCT02403505
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 20
- From 28 Dec 2021 to the primary completion date, 28 Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Thrombosis
- Allergy
- Symptoms of rectal cancer
- Metastasis of rectal cancer
- Evidence of critical illness
Other
- Pregnant
- TB positive participant is positive IGRA blood test with TB antigens.
Who the study is looking for
- Clinical Rectal Cancer Diagnosis Stage 0 - IIA
- Clinical Rectal Cancer Diagnosis without symptoms
- Clinical Rectal Cancer Diagnosis without metastasis
- Positive testing CEA by blood-drawing
- TB negative participant is negative IGRA blood test with TB antigens.
Criteria the registry did not label
- Conducting an early phase clinical trial to assess CEA Antigen Presentation Therapeutic Biological Product Mix that suggests the potential for clinical benefit of CEA positive rectal cancer patients.
- 20 CEA Positive Rectal Cancer Patients
Age in the registry: 24 years to 64 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Medicine Invention Design, Inc. (MIDI) - c/o - IORG0007849 - NPI-1023387701 Coordinator of this site? Confirm its status | Rockville | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.